Date: 2017-08-15
Type of information: Private placement
Company: Dynavax (USA - CA)
Investors:
Amount: $80.8 million
Funding type: private placement
Planned used:
- Dynavax anticipates using the net proceeds from the proposed offering to fund activities associated with preparing for the anticipated U.S. commercial launch of Heplisav-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted]. In addition, net proceeds from the offering will support continuing the clinical development of its lead investigational cancer immunotherapeutic product candidates, SD-101 and DV281, continuing research and development activities, and for other general corporate purposes, including working capital.
Others:
- • On August 15, 2017, Dynavax Technologies Corporation announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Dynavax at a price to the public of $15.00 per share. The net proceeds to Dynavax from this offering were approximately $80.8 million, after deducting the underwriting discount and other estimated offering expenses payable by Dynavax.
- • On August 9, 2017, Dynavax announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at a price to the public of $15.00 per share. The gross proceeds to Dynavax from this offering are expected to be approximately $75 million, before deducting the underwriting discount and other estimated offering expenses payable by Dynavax. Dynavax has granted the underwriters a 30-day option to purchase at the public offering price up to an aggregate of 750,000 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on or about August 15, 2017, subject to customary closing conditions.
- • On August 8, 2017, Dynavax announced that it intends to offer and sell $125.0 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock to cover over-allotments, if any. Cowen, RBC Capital Markets and William Blair are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. is acting as lead manager for the offering.
Therapeutic area: Infectious diseases
Is general: Yes
